Abstract 34P
Background
Resilience to stress is a central phenotype underlying cancer cell biology. Cancer resilience empowers cell growth and survival in the face of harsh microenvironments, cytotoxic therapies, and loss of normal cellular regulatory processes. By understanding the mechanisms underlying cancer cell resilience, we may develop therapies which constrain tumors generally or synergize with existing drugs. Here, we sought to identify yet-unknown mechanisms by which cancer cells orchestrate resilience.
Methods
Using genome-scale CRISPR-Cas9 screening data from over 700 unique cancer cell lines (DepMap project), we developed a guilt-by-association “coessentiality” approach to identify genes involved cellular stress response signaling. We then used a combination of molecular biology, evolutionary biology, and computational biology approaches to validate predictions.
Results
Using an unbiased functional genomic approach and subsequent molecular validation, we identified HAPSTR1 (formerly: C16orf72) as a gene which becomes particularly important to cancer cells under stress conditions (e.g., DNA damage, protein aggregation, nutrient starvation). HAPSTR1, despite conservation through worms, yeast, and plants, had no known function. We found that HAPSTR1 encodes a dimeric protein which enables nuclear localization of HUWE1, an otherwise cytoplasmic ubiquitin ligase. Additionally, we show that mammals have a second HAPSTR gene, HAPSTR2 (formerly: RP11-364B14.3), which formed via an atypical evolutionary mechanism and functions to buffer the HAPSTR-HUWE1 pathway in specific cancer subsets.
Conclusions
Altogether, we present a new gene family and biochemical pathway leveraged by cancer cells to empower resilience. Disruption of this pathway broadly impairs stress response regulation and may thus be relevant to understanding and targeting resilience in human tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Institutes of Health (NIH-USA).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - A one-tube multiplex methylation-specific droplet digital PCR assay for identification of ctDNA biomarkers in anal squamous cell carcinoma
Presenter: Karen-Lise Spindler
Session: Poster session 07
95P - Baseline-informed longitudinal monitoring of lung cancer by cell-free DNA methylation profiles
Presenter: Chunxia Su
Session: Poster session 07
96P - A novel strategy for single-nucleus RNA-seq of frozen PAXgene blood: A clinical alternative to single-cell RNA-seq of cryopreserved PBMCs
Presenter: Asaf Rotem
Session: Poster session 07
97P - GENIE-seq: A novel methylation sequencing method for effective and accurate identification of methylation markers from cfDNA
Presenter: Zhaoyun Ding
Session: Poster session 07
98P - Translating cancer tissue methylation to cell-free DNA methylation for minimally invasive cancer detection
Presenter: Edward Post
Session: Poster session 07
99P - Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial
Presenter: Kyoungmin Lee
Session: Poster session 07
100P - Predicting tumor ER and HER2 status using a cell-free RNA liquid biopsy assay
Presenter: Lee Schwartzberg
Session: Poster session 07
101P - Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC
Presenter: Fang Wu
Session: Poster session 07